ERBB2 and breast cancer: Jia et al. [20] categorized 152 ER-high/HER2-negative BC patients receiving first-line CDK-4/6 inhibitors into three groups (PgR-low, -negative, and -high) by establishing a PgR level cut-off at 10%.